WILMINGTON, Del., March 28, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Aerojet Rocketdyne Holdings, Inc. (NYSE:AJRD)?
- Did you purchase your shares between October 15, 2013 and February 1, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of Aerojet Rocketdyne Holdings, Inc. (“Aerojet” or the “Company”) (NYSE:AJRD) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Central District of California on behalf of all persons or entities that purchased the common stock of Aerojet between October 15, 2013 and February 1, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you wish to serve as lead plaintiff, you must move the Court no later than April 11, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of Aerojet during the Class Period, or purchased shares prior to the Class Period and still hold Aerojet, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/aerojet-rocketdyne-holdings-inc-ajrd.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com


AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 



